LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

Home・Akciju saraksts・CareDx Inc

CareDx Inc

Atvērts

SektorsVeselības aprūpe

21.18 2.12

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.5

Max

21.79

Galvenie mērījumi
By Trading Economics
Ienākumi	6.9M 2.8M
Pārdošana	9.3M 118M
P/E Sektora vidējais	14.645 49.701
EPS	0.34
Peļņas marža	2.387
Darbinieki	761
EBITDA	5.6M 7.1M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+16.93% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-68M 1.1B
Iepriekšējā atvēršanas cena	19.06
Iepriekšējā slēgšanas cena	21.18

Ziņu noskaņojums

By Acuity

50%

159 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

14.77 / 18.49 Atbalsts un pretestība

CareDx Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 23:31 UTC

Karstas akcijas

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026. g. 20. maijs 22:52 UTC

Galvenie tirgus virzītāji

Osisko Shares Fall on Planned Convertible Notes Offering

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 20. maijs 23:44 UTC

Peļņas

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026. g. 20. maijs 23:35 UTC

Tirgus saruna

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026. g. 20. maijs 23:30 UTC

Tirgus saruna

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026. g. 20. maijs 23:15 UTC

Tirgus saruna

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026. g. 20. maijs 23:14 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026. g. 20. maijs 23:02 UTC

Tirgus saruna

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 22:27 UTC

Tirgus saruna

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026. g. 20. maijs 22:14 UTC

Tirgus saruna

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026. g. 20. maijs 22:10 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026. g. 20. maijs 22:00 UTC

Peļņas

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026. g. 20. maijs 21:38 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026. g. 20. maijs 21:27 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026. g. 20. maijs 21:20 UTC

Peļņas

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026. g. 20. maijs 21:19 UTC

Peļņas

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026. g. 20. maijs 21:18 UTC

Peļņas

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026. g. 20. maijs 21:16 UTC

Peļņas

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CareDx Inc Prognoze

Cenas mērķis

By TipRanks

16.93% augšup

Prognoze 12 mēnešiem

Vidējais 24.73 USD 16.93%

Augstākais 28 USD

Zemākais 21 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CareDx Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CareDx Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

14.77 / 18.49Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bearish.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

159 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.